ADOCIA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.12.15	Adocia Announces Its Financial Calendar for 2016 (Businesswire)
15.12.15	Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 (Businesswire)
11.12.15	Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 (Businesswire)
25.11.15	Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes (Businesswire)
04.11.15	Adocia Announces Positive Phase 1b Results on the Post-Meal Effect of BioChaperone® Combo in Patients with Type 1 Diabetes (Businesswire)
13.10.15	ADOCIA Reports Third Quarter 2015 Financial Results (Businesswire)
06.10.15	Adocia and Lilly Initiate a Phase 1b Study Evaluating Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes Using Insulin Pump Therapy (Businesswire)
05.10.15	Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon (Businesswire)
30.09.15	Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes (Businesswire)
17.09.15	ADOCIA: additional contribution to the liquidity agreement (Businesswire)
27.08.15	Adocia and Lilly Initiate New Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes (Businesswire)
24.08.15	Adocia Initiates a Clinical Study on a High Concentration Formulation of the Ultra-Rapid Insulin BioChaperone Lispro (Businesswire)
21.07.15	Adocia Presents Financial Results for the First Half of 2015 Highlighting Strong Growth (Businesswire)
10.07.15	Adocia Initiates Two Clinical Studies on Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, BioChaperone® Combo (Businesswire)
26.06.15	Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes (Businesswire)
15.06.15	Adocia is Now Integrated into the CAC Mid 60 and SBF 120 Indices (Businesswire)
28.05.15	Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 (Businesswire)
26.05.15	Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) (Businesswire)
04.05.15	Adocia Announces the Release of Its Reference Document, Containing the Annual Financial Report, for the Year 2014 (Businesswire)
29.04.15	Adocia is Now Integrated into the EnterNext Tech 40 Index (Businesswire)
20.04.15	Adocia to Hold Its Annual Shareholders’ Meeting on May 27, 2015 in Lyon (Businesswire)
14.04.15	Adocia Announces First Quarter 2015 Results (Businesswire)
27.03.15	Adocia Successfully Raises Approx. €32m from Healthcare Specialist Investors (Businesswire)
26.03.15	Adocia to Raise Capital in a Private Placement of New Shares (Businesswire)
16.03.15	Adocia Will Present Its 2014 Annual Results and Its Perspectives of Growth During a Conference Call : Tuesday March 17, 2015 at 6:00 PM (CET) (Businesswire)
10.03.15	Adocia Reports a Strengthened Cash Position and Intensifies Clinical Development (Businesswire)
05.03.15	Adocia Opens a Subsidiary in the USA and is Pleased to Appoint Simon Bruce, MD and Stephen Daly (Businesswire)
17.02.15	ADOCIA: Annual Revenue and Net Cash Position for 2014 (Businesswire)
10.02.15	Adocia: Modification of the Means Allocated to the Liquidity Agreement (Businesswire)
05.02.15	Adocia Reports Positive Results from Phase IIa Clinical Study of Fast-Acting Human Insulin, HinsBet® (Businesswire)
20.01.15	Adocia Initiates a Clinical Study on the Post-Meal Effect of Ultra-Rapid BioChaperone Lispro Insulin Formulation (Businesswire)
09.01.15	Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
29.12.14	Adocia Announces Its Financial Calendar for 2015 (Businesswire)
22.12.14	ADOCIA: Shareholder Newsletter (Businesswire)
19.12.14	Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology (Businesswire)
16.10.14	ADOCIA Announces Third-Quarter Financial 2014 Results (Businesswire)
30.09.14	ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry (Businesswire)
09.09.14	Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes (Businesswire)
25.08.14	Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer (Businesswire)
24.07.14	Adocia Reports Operational and Financial Results for the First Half of 2014 (Businesswire)
10.07.14	Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
09.07.14	Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes (Businesswire)
10.06.14	Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 (Businesswire)
04.06.14	Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 (Businesswire)
27.05.14	Adocia Initiates ADR program (American Deposit Receipt) in the United States (Businesswire)
20.05.14	Adocia Initiates a Dose-Response Phase IIa Clinical Study of Ultra-fast Acting BioChaperone® Lispro (Businesswire)
19.05.14	Adocia Announces the Signature of a Liquidity Agreement with Kepler Capital Markets SA (Businesswire)
17.04.14	ADOCIA Announces First-Quarter 2014 Results (Businesswire)
09.04.14	Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone® Lispro (Businesswire)
25.03.14	Adocia announces financial results for 2013 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ADOCIA

Aktien Top/Flop

Meistgelesene Nachrichten